SCYNEXIS Stock

SCYNEXIS EBITDA Margin

The EBITDA Margin of SCYNEXIS (SCYX) as of Aug 16, 2026 is -990.84 %. In the previous year, EBITDA Margin was 51.85 % — a change of -2,010.83% (lower).

EBITDA Margin

-990.84 %

YoY

-2,010.83%

Last updated:

EBITDA Margin of SCYNEXIS is 2026 -990.84 % . EBITDA Margin of SCYNEXIS was 2025 51.85 % . It decreases by -2,010.83% lower compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

EBITDA Margin of SCYNEXIS is -990.84 % in 2026.

EBITDA Margin of SCYNEXIS changed from 51.85 % to -990.84 %, representing a -2,010.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's SCYNEXIS with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

Margins — SCYNEXIS

All Key Metrics — SCYNEXIS